Testing a Point Score Tool to Predict 30-Day Survival in Adults With Metastatic Cancer Receiving Palliative Radiation Therapy

What this Trial Is About

Researchers are evaluating a survival prediction tool developed by Lee et al for patients with metastatic cancer referred to radiation oncology for palliative treatments. This phase II clinical trial aims to test the tools ability to predict 30-day survival based on objective data such as laboratory values, emergency room visits, and primary cancer origin. Patients will be assigned a score reflecting their mortality risk, categorized as low, intermediate, or high risk. The study uses a single-arm design where each participant receives a survival prediction score ranging from 0 to 20, with higher scores indicating worse survival prognosis. The prediction tool incorporates several laboratory measures and clinical history to calculate this score at enrollment. Patients may or may not receive palliative radiation therapy as part of their care, and completing radiation treatment is not required for participation. Risk groups are defined as low 0-6, intermediate 7-13, and high 14-20 scores. Participants will be monitored for survival and quality of life at 30, 90, and 365 days after enrollment. Quality of life will be assessed using the FACIT-Pal-14 questionnaire. Follow-up visits may be in person or virtual. The primary outcome is 30-day survival of the high-risk group, while secondary outcomes include survival across all risk groups at various time points and patient-reported quality of life. The total study duration for participants is one year from enrollment.

Prospective Validation of a Points Score System Predicting 30-day Survival